<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219268</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGD013-01</org_study_id>
    <nct_id>NCT03219268</nct_id>
  </id_info>
  <brief_title>A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms</brief_title>
  <official_title>A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this Phase 1 study is to characterize the safety and tolerability of&#xD;
      tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid&#xD;
      tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors.&#xD;
      Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of&#xD;
      tebotelimab will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 18, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose escalation followed by Cohort Expansion Phase at the MTD.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy)</measure>
    <time_frame>24 months</time_frame>
    <description>Safety&#xD;
Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>24 months</time_frame>
    <description>maximum tolerated or maximum administered dose of tebotelimab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (tebotelimab plus margetuximab)</measure>
    <time_frame>24 months</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration versus Time Curve (AUC) of tebotelimab and MGD013 plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of tebotelimab and tebotelimab plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum (peak) plasma concentration (Tmax) of tebotelimab and tebotelimab plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough) of tebotelimab and tebotelimab plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>Ctrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance of the drug from plasma (CL) of tebotelimab and tebotelimab plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss) of tebotelimab and tebotelimab plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>Vss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of tebotelimab and tebotelimab plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with anti-drug antibody</measure>
    <time_frame>24 months</time_frame>
    <description>immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Preliminary anti-tumor activity of tebotelimab and tebotelimab plus margetuximab</measure>
    <time_frame>36 months</time_frame>
    <description>Preliminary anti-tumor activity of MGD013 and MGD013 plus margetuximab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years after end of treatment visit</time_frame>
    <description>Time from start of treatment to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Hematologic Neoplasms</condition>
  <condition>Ovarian Cancer</condition>
  <condition>HER2-positive Advanced Solid Tumors</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Small-cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Cervical Cancer</condition>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>tebotelimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tebotelimab administered IV once every 2 weeks for up to 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tebotelimab + margetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tebotelimab administered in combination with margetuximab IV once every 3 weeks for up to 32 3-week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tebotelimab</intervention_name>
    <description>Anti-PD-1, anti-LAG-3 bispecific DART protein</description>
    <arm_group_label>tebotelimab</arm_group_label>
    <arm_group_label>tebotelimab + margetuximab</arm_group_label>
    <other_name>MGD013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>margetuximab</intervention_name>
    <description>anti-HER2 monoclonal antibody</description>
    <arm_group_label>tebotelimab + margetuximab</arm_group_label>
    <other_name>MGAH22</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven, locally advanced unresectable or metastatic solid tumors (or&#xD;
             hematologic malignancies, Cohort Expansion only) for whom no approved therapy with&#xD;
             demonstrated clinical benefit is available or standard treatment was declined.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Tissue specimen available for retrospective analysis of PD-1, PD-L1, LAG-3, and MHC-II&#xD;
             expression&#xD;
&#xD;
          -  Acceptable laboratory parameters&#xD;
&#xD;
        HER2+ Cohort:&#xD;
&#xD;
        - Locally advanced or metastatic HER2+ locally advanced or metastatic solid tumors,&#xD;
        regardless of organ of origin.&#xD;
&#xD;
        i. The cancer must have progressed following standard therapy, or has progressed during or&#xD;
        after HER2-directed therapy if approved and available for patients with HER2+ breast,&#xD;
        gastric, or gastroesophageal junction cancer.&#xD;
&#xD;
        ii. History of HER2 positivity defined as 3+ by IHC or 2+ by IHC in combination with in&#xD;
        situ hybridization (ISH) positivity most recent tumor biopsy.&#xD;
&#xD;
          -  All patients in the HER2+ cohort must be willing to provide consent for a baseline and&#xD;
             on-treatment tumor biopsy during the screening period and within 14 days prior to&#xD;
             Cycle 3 Day 1. Exceptions may be made based on a medical contraindication at the&#xD;
             discretion of the Sponsor's Medical Monitor. This requirement will be discontinued&#xD;
             after an adequate number of samples are collected, as determined by the Sponsor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic central nervous system (CNS) metastases or primary CNS lymphoma&#xD;
&#xD;
          -  History of allogeneic bone marrow, stem-cell, or solid organ transplant&#xD;
&#xD;
          -  History of known or suspected autoimmune disease with the specific exceptions of&#xD;
             vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic&#xD;
             treatment (within the past 2 years), and patients with a history of Grave's disease&#xD;
             that are now euthyroid clinically and by laboratory testing.&#xD;
&#xD;
          -  Treatment with any systemic chemotherapy within 3 weeks prior to the initiation of&#xD;
             study drug; treatment with biologics or investigational therapy within the 4 weeks&#xD;
             prior to the initiation of study drug.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to the initiation of study drug.&#xD;
&#xD;
          -  Prior treatment with combination of monoclonal antibodies against PD-1 and LAG-3&#xD;
             (Cohort Expansion only).&#xD;
&#xD;
          -  Treatment with radiation therapy within 2 weeks prior to the initiation of study drug.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease.&#xD;
&#xD;
          -  QTcF prolongation &gt; 480 milliseconds&#xD;
&#xD;
          -  HER2+ cohort: left ventricular ejection fraction less than 50%&#xD;
&#xD;
          -  Clinically significant pulmonary compromise, including a requirement for supplemental&#xD;
             oxygen use to maintain adequate oxygenation.&#xD;
&#xD;
          -  Active pneumonitis or history of non-infectious pneumonitis.&#xD;
&#xD;
          -  Clinically significant gastrointestinal disorders.&#xD;
&#xD;
          -  Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral&#xD;
             treatment within 7 days prior to the initiation of study drug.&#xD;
&#xD;
          -  Known history of positive testing for human immunodeficiency virus or history of&#xD;
             acquired immune deficiency syndrome.&#xD;
&#xD;
          -  Known history of hepatitis B (except in hepatocellular carcinoma) or hepatitis C&#xD;
             infection or known positive test for hepatitis B surface antigen, hepatitis B core&#xD;
             antigen, or hepatitis C polymerase chain reaction (PCR)&#xD;
&#xD;
          -  Vaccination with any live virus vaccine within 4 weeks prior to the initiation of&#xD;
             study drug administration. Inactivated annual influenza vaccination is allowed&#xD;
&#xD;
          -  Dementia or altered mental status that would preclude understanding and rendering of&#xD;
             informed consent&#xD;
&#xD;
          -  Confirmed or presumed COVID-19/SARS-CoV-2 infection. While SARS-CoV-2 testing is not&#xD;
             mandatory for study entry, testing should follow local clinical practice&#xD;
             guidelines/standards. Patients with a positive test result for SARS-CoV-2 infection,&#xD;
             known asymptomatic infection, or presumed infection are excluded. Patients may be&#xD;
             considered eligible after a resolved SARS-CoV-2 infection once he or she remains&#xD;
             afebrile for at least 72 hours and after other SARS-CoV-2-related symptoms have fully&#xD;
             recovered to baseline for a minimum of 72 hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Sumrow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital and Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center, The University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health Melbourne</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Complex Oncology Center - Burgas&quot; EOOD</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda&quot; EAD, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Serdika&quot; EOOD, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Kraków</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>31-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioVirtus Research Site Sp. Z o.o. / Biovirtus Centrum Medyczne</name>
      <address>
        <city>Józefów</city>
        <state>Masovian</state>
        <zip>05-410</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-034</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med-Polonia Sp. z o.o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START Madrid-CIOCC, Hospital HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise &quot;Cherkassy Regional Oncology Dispensary&quot; of Cherkassy Regional Council</name>
      <address>
        <city>Cherkassy</city>
        <state>Cherkasy Region</state>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Podillia Regional Center of Oncology of Vinnytsia Regional Council</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnytsa Region</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise &quot;City Clinical Hospital #4&quot; of Dnipro City Council</name>
      <address>
        <city>Dnipro</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise &quot;Prykarpatsky Clinical Oncological Centre of Ivano-Frankivska Regional Council&quot;</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise of Sumy Regional Council &quot;Sumy Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Sumy</city>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise &quot;Central City Clinical Hospital of Uzhhorod City Council&quot;, City Oncology Center, State Higher Educational Institution &lt;&lt;Uzhhorod National University&gt;&gt;</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Margetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

